Fifteen RCTs (n=450) were included. The quality of included studies was generally high with an average score of 12.7 (range: 9 to 16). Four RCTs reported a sample size calculation. Sample size ranged from 9 to 62. Ten RCTs employed a crossover design.
All antiglaucoma drugs included in this review showed a statistically significant peak absolute intraocular pressure reduction relative to baseline. The trough and diurnal curve absolute intraocular pressure reduction measurements were statistically significant for timolol, brimonidine, latanoprost and bimatoprost.
A statistically significant peak relative intraocular pressure reduction was reported for timolol, dorzolamide, brinzolamide, brimonidine, latanoprost and bimatoprost. The trough and diurnal curve relative intraocular pressure reductions were statistically significant for timolol, brimonidine, latanoprost and bimatoprost.
No evidence of publication bias was found.